Clinical Trial Update: A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs [Phase 2]

View source ↗

Summary

A Phase II, single-arm trial evaluating camrelizumab in combination with GEMOX for unresectable gallbladder cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gallbladder Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)
• Gemcitabine (Gemcitabine)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Unresectable Gallbladder Cancer | Phase 2 | Status: RECRUITING